Tags

Type your tag names separated by a space and hit enter

Loracarbef (LY163892) versus amoxicillin/clavulanate in bronchopneumonia and lobar pneumonia.
Clin Ther. 1992 Mar-Apr; 14(2):254-67.CT

Abstract

In a single-blind study, 134 patients with bronchopneumonia or lobar pneumonia were randomly assigned to receive 400 mg of loracarbef twice daily or 500/125 mg of amoxicillin/clavulanate three times daily for 10 to 14 days. Treatment efficacy was evaluated in 38 patients treated with loracarbef and in 39 treated with amoxicillin/clavulanate in whom pre-treatment positive cultures of pathogens susceptibile to the study drugs were isolated. Streptococcus pneumoniae and Haemophilus influenzae were cultured as single pathogens in 40.3% of the evaluable patients. Among the evaluable patients, 100% of the loracarbef group and 92.3% of the amoxicillin/clavulanate group had a favorable clinical response (cure or improvement). Bacteriologic response was favorable and the pathogen was eliminated or presumed eliminated in 97.4% of the loracarbef-treated patients and in 92.3% of the amoxicillin/clavulanate-treated patients. Treatment was discontinued in one loracarbef-treated patient because Ludwig's angina, unrelated to the study drug, was diagnosed and in five amoxicillin/clavulanate-treated patients because of diarrhea (two patients), rash (two patients), and nausea and vomiting (one patient). Diarrhea, the most frequently cited adverse event, was reported by 6.1% of the loracarbef-treated patients and 11.8% of the amoxicillin/clavulanate-treated patients. Asthenia was reported by 0% and 8.8% of the loracarbef and amoxicillin/clavulanate patients, respectively. It is concluded that both loracarbef and amoxicillin/clavulanate are safe and effective in the treatment of acute bacterial pneumonia.

Authors+Show Affiliations

Lilly Research Laboratories, Indianapolis, Indiana.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

1611648

Citation

Hyslop, D L., et al. "Loracarbef (LY163892) Versus Amoxicillin/clavulanate in Bronchopneumonia and Lobar Pneumonia." Clinical Therapeutics, vol. 14, no. 2, 1992, pp. 254-67.
Hyslop DL, Jacobson K, Guerra FJ. Loracarbef (LY163892) versus amoxicillin/clavulanate in bronchopneumonia and lobar pneumonia. Clin Ther. 1992;14(2):254-67.
Hyslop, D. L., Jacobson, K., & Guerra, F. J. (1992). Loracarbef (LY163892) versus amoxicillin/clavulanate in bronchopneumonia and lobar pneumonia. Clinical Therapeutics, 14(2), 254-67.
Hyslop DL, Jacobson K, Guerra FJ. Loracarbef (LY163892) Versus Amoxicillin/clavulanate in Bronchopneumonia and Lobar Pneumonia. Clin Ther. 1992 Mar-Apr;14(2):254-67. PubMed PMID: 1611648.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Loracarbef (LY163892) versus amoxicillin/clavulanate in bronchopneumonia and lobar pneumonia. AU - Hyslop,D L, AU - Jacobson,K, AU - Guerra,F J, PY - 1992/3/1/pubmed PY - 1992/3/1/medline PY - 1992/3/1/entrez SP - 254 EP - 67 JF - Clinical therapeutics JO - Clin Ther VL - 14 IS - 2 N2 - In a single-blind study, 134 patients with bronchopneumonia or lobar pneumonia were randomly assigned to receive 400 mg of loracarbef twice daily or 500/125 mg of amoxicillin/clavulanate three times daily for 10 to 14 days. Treatment efficacy was evaluated in 38 patients treated with loracarbef and in 39 treated with amoxicillin/clavulanate in whom pre-treatment positive cultures of pathogens susceptibile to the study drugs were isolated. Streptococcus pneumoniae and Haemophilus influenzae were cultured as single pathogens in 40.3% of the evaluable patients. Among the evaluable patients, 100% of the loracarbef group and 92.3% of the amoxicillin/clavulanate group had a favorable clinical response (cure or improvement). Bacteriologic response was favorable and the pathogen was eliminated or presumed eliminated in 97.4% of the loracarbef-treated patients and in 92.3% of the amoxicillin/clavulanate-treated patients. Treatment was discontinued in one loracarbef-treated patient because Ludwig's angina, unrelated to the study drug, was diagnosed and in five amoxicillin/clavulanate-treated patients because of diarrhea (two patients), rash (two patients), and nausea and vomiting (one patient). Diarrhea, the most frequently cited adverse event, was reported by 6.1% of the loracarbef-treated patients and 11.8% of the amoxicillin/clavulanate-treated patients. Asthenia was reported by 0% and 8.8% of the loracarbef and amoxicillin/clavulanate patients, respectively. It is concluded that both loracarbef and amoxicillin/clavulanate are safe and effective in the treatment of acute bacterial pneumonia. SN - 0149-2918 UR - https://www.unboundmedicine.com/medline/citation/1611648/Loracarbef__LY163892__versus_amoxicillin/clavulanate_in_bronchopneumonia_and_lobar_pneumonia_ DB - PRIME DP - Unbound Medicine ER -